Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Updates for Treatment of Blistering Diseases
Description
The speaker discussed recent advancements in treating two common autoimmune blistering diseases: pemphigus vulgaris and bullous pemphigoid. For pemphigus vulgaris, the talk covered three emerging treatment categories: targeting autoantibody levels, autoreactive B cells, and cell therapy. Notable mentions included the neonatal Fc receptor antagonists, which have failed to show promise in recent trials, and BTK inhibitors, which are undergoing further evaluation after showing initial efficacy in Phase 2 trials. Additionally, cell therapy, particularly desmoglein CAR T cell therapy, remains a focus despite past studies indicating limited efficacy. In contrast, bullous pemphigoid presents more excitement with multiple therapies under exploration, including the use of dupilumab, which has demonstrated significant improvement rates among patients. Other developments include the investigation of eosinophil-targeting treatments and complementary agents that may contribute to disease management. The speaker emphasized the potential of several ongoing clinical trials and expressed optimism about the future landscape of treatments for both diseases, despite some setbacks in previous studies.
View moreConclusions
- There are currently no effective neonatal Fc receptor antagonists in trial for pemphigus, as past trials have failed.
- Development of targeted B cell therapies such as BTK inhibitors and anti-BAFF agents is in progress, but some trials have been terminated.
- Cell therapies including autologous polyclonal Tregs and Dsg3 chimeric autoantibody receptor T cell therapy show promise but have faced recruitment issues or have been terminated due to challenges in study execution.
- Dupilumab shows significant disease control in bullous pemphigoid (BP) patients, with many achieving disease control within four weeks.
- Omalizumab is another potential treatment option for BP, but doubts remain about its efficacy without the presence of elevated IgE levels.
- Emerging therapies for BP include a range of monoclonal antibodies targeting eosinophil activity and complement components, with some showing promising preliminary results.
- Optimizing current therapies by combining different agents, such as the potential use of rituximab with omalizumab, is underway to enhance treatment responses.
- Key focus areas for future research include improving the efficacy of existing biologics and developing new agents specifically targeting the pathways involved in pemphigus and BP.
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
- Werth VP, Culton D, Blumberg L, Humphries J, Blumberg R, Hall R. FcRn blockade with SYNT001 for the treatment of pemphigus. J Invest Dermatol. 2018;138:S92. doi:10.1016/j.jid.2018.03.546
- Werth VP, Culton DA, Concha JS, et al. Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. J Invest Dermatol. 2021 Dec;141(12):2858-2865.e4. doi: 10.1016/j.jid.2021.04.031. Epub 2021 Jun 12. PubMed ID: 34126109.
- Daneshvar E, Tavakolour S, Mahmoudi H, et al. Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents. Int J Dermatol. 2023 Apr;62(4):567-574. doi: 10.1111/ijd.16363. Epub 2022 Jul 27. PubMed ID: 35894225.
- Patsatsi A and Murrell DF. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. Front Med (Lausanne). 2021;8:708071. Published online 2021 Aug 10. doi:10.3389/fmed.2021.708071. PubMed ID: 34447768.
- Ellebrecht CT, et al. Setting the target for pemphigus vulgaris therapy. JCI Insight. 2017 Mar 9;2(5):e92021. doi: 10.1172/jci.insight.92021.
- Zeng FA, Murrell DF. Bullous pemphigoid-What do we know about the most recent therapies? Front Med (Lausanne). 2022;9:1057096. Published online 2022 Nov 3. doi:10.3389/fmed.2022.1057096 PubMed ID: 36405625.
- Kaye A, et al. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol. 2018 Oct 1;154(10):1225-1226. doi:10.1001/jamadermatol.2018.2526.
- Yu KK, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014 Sep;71(3):468-74. doi: 10.1016/j.jaad.2014.04.053. Epub 2014 Jun 20.
- Lee J, Werth VP, Hall RP, III, Eming R, Fairley JA, Fajgenbaum DC, et al. Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference. Front Med. (2018) 5:306. doi: 10.3389/fmed.2018.00306.
- Zhang Q, Hu Z, et al. Prospective Evaluation of Safety and Tolerability of Monoclonal Antibodies Targeting IL-5. J Clin Immunol. 2021;41(1):61-72. doi: 10.1007/s10875-020-00827-2.